Boardroom Alpha
Boardroom Alpha
TRNS · Current Report (Form 8-K) · Filed March 9, 2026

Transcat Inc — Current Report (Form 8-K)

Form
8-K
Filed
March 9, 2026
Period
Mar 6, 2026
Ticker
TRNS
Accession
0001206774-26-000129
Boardroom Alpha · Filing insights

Transcat names Jaime Irick as CEO effective March 29, 2026; Rudow resigns from the Board to a senior advisory role.

About Transcat Inc
Market cap
$800M
1Y TSR
+19.0%
3Y TSR
−5.0%
Board grade
C+
Sector
Industrials
CEO
Jaime A Irick
Last annual meeting: Sep 9, 2026 · View full Transcat Inc profile →

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)  March 6, 2026

 

Transcat, Inc.
(Exact name of registrant as specified in its charter)

 

Ohio 000-03905 16-0874418
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

35 Vantage Point Drive, Rochester, New York 14624
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code  (585) 352-7777

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.50 par value TRNS Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement

 

To the extent required by Item 1.01 of Form 8-K, the information contained in Item 5.02 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Chief Executive Officer Transition

 

On March 6, 2026, the Board of Directors (the “Board”) of Transcat, Inc. (the “Company”) appointed Jaime Irick to become the Company’s President and Chief Executive Officer as of March 29, 2026 (the “Effective Date”). Mr. Irick, age 51, most recently served as the Chief Executive Officer of The Pittsburgh Paints Company, a multi-billion dollar paints, stains and building products company serving homeowners and professionals, from December 2024 to February 2025. Mr. Irick served as Senior Vice President, Architectural Coatings, U.S. and Canada, and Traffic Solutions of PPG Industries, Inc., a global manufacturer and distributor of paints, coatings and specialty products, where he led a team of 7,000 employees to deliver innovative products and services for their customers, from May 2022 to December 2024 after having served as Vice President, Architectural Coatings, U.S. and Canada, from May 2019 to May 2022. Prior to his service at PPG, Mr. Irick was Vice President and President, Life Fitness, for Brunswick Corporation from January 2017 to December 2018. From 2003 to 2016, he held roles with increasing levels of responsibility in General Electric Company, including as a GE Company Officer. Before his business career, Mr. Irick served as a Field Artillery Officer in the U.S. Army for five years. Mr. Irick currently serves as a member of the board of directors of Illinois Tool Works Inc. (NYSE: ITW), a Fortune 300 industrial manufacturer. As previously disclosed, Lee D. Rudow will resign from the Board and transition to a senior advisory role effective as of March 28, 2026 to provide continuity for the Company through the fiscal year ending March 27, 2027 (“fiscal 2027”). Mr. Rudow’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Also on March 6, 2026, the Board appointed Mr. Irick to fill the vacancy created by Mr. Rudow’s resignation from the Board for a term expiring at the Company’s 2027 annual meeting of shareholders. Once his appointment is effective, Mr. Irick will serve on the Executive Committee.

 

On March 6, 2026, the Company entered into an executive employment agreement (the “Employment Agreement”) with Mr. Irick that will become effective on the Effective Date. Pursuant to the Employment Agreement, Mr. Irick will be entitled to an initial base salary of $650,000 per annum, a target performance-based cash incentive award of 100% of his base salary for fiscal 2027, and equity incentive awards under the Company’s long-term incentive compensation plan, consistent with the Company’s historical awards for executive officers, with a target value of $2.3 million for fiscal 2027. Mr. Irick will be subject to the Company’s stock ownership objectives for directors and executive officers and is eligible to participate in and receive benefits under the Company’s standard benefit programs.

 

The initial term of the Employment Agreement is three years, which will automatically renew for one-year periods thereafter. If the Employment Agreement is not renewed by the Company, if Mr. Irick terminates the Employment Agreement for good reason, or if the Company terminates Mr. Irick without cause, then he will be entitled to severance pay in an amount equal to 12 months of his base salary, continuing healthcare coverage, and earned cash bonus. If Mr. Irick’s employment is terminated in connection with a change in control, Mr. Irick will be entitled to certain payment and benefits in an amount equal to his full salary, bonus and benefits for 24 months after the date of termination of his employment as well as the immediate vesting of certain equity awards pursuant to the Company’s Form of Agreement for Severance Upon Change in Control, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2024.

 

Other than as disclosed in this Current Report, there are no arrangements or understandings between Mr. Irick and any other person with respect to his appointment as President and Chief Executive Officer, nor with respect to his appointment to serve as a director of the Board, and there are no family relationships between him and any director or executive officer of the Company. Neither Mr. Irick, nor any of his immediate family has been a party to any transaction with the Company, nor is any such transaction currently proposed, that would be reportable under Item 404(a) of Regulation S-K.

 

 

 

 

Chief Financial Officer Compensation

 

On March 6, 2026, the Compensation Committee of the Board approved an increase in compensation for Thomas L. Barbato, the Company’s Chief Financial Officer, effective as of the Effective Date. For fiscal 2027, Mr. Barbato will be entitled to a base salary of $480,000 per annum and a target performance-based cash incentive award of 70% of his base salary.

 

Indemnification Agreement

 

On March 6, 2026, the Board approved an updated form of indemnification agreement that the Company intends to enter into with its current and future directors and executive officers (individually, the “Indemnification Agreement” and collectively, the “Indemnification Agreements”). The Indemnification Agreement will, among other things, require the Company to indemnify each director and executive officer to the fullest extent permitted by law, including indemnification of expenses and certain judgments, penalties, fines and settlement amounts incurred by the director or executive officer in any proceeding arising out of such person’s services as a director or executive officer. The Indemnification Agreement also sets forth certain exclusions from such indemnification rights, procedures with respect to requesting and obtaining indemnification, advancement of expenses and other customary provisions. The Indemnification Agreement is intended to provide indemnification rights to the fullest extent permitted under the Ohio General Corporation Law and shall be in addition to any other rights the directors and executive officers may have under the Company’s Articles of Incorporation, as amended, or Code of Regulations, as amended.

 

The foregoing descriptions of the Employment Agreement and Indemnification Agreement do not purport to be complete and are subject to, and are qualified in their entirety by reference to, the full text of the Employment Agreement and Indemnification Agreement, which are attached as Exhibit 10.1 and 10.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

 

Item 7.01Regulation FD Disclosure.

 

On March 9, 2026, the Company issued a press release regarding the matters described in this Current Report on Form 8-K. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under such section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
#10.1   Executive Employment Agreement, between Transcat, Inc and Jaime Irick, effective as of March 29, 2026.
#10.2   Form of Indemnification Agreement
99.1   Transcat, Inc. Press Release dated March 9, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

#Management contract or compensatory plan or arrangement.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      TRANSCAT, INC.
       
Dated: March 9, 2026   By: /s/ Thomas L. Barbato
    Name:  Thomas L. Barbato
    Title: Senior Vice President of Finance and Chief Financial Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Transcat Inc (TRNS)

Reference

Frequently asked questions

When did Transcat Inc file this 8-K?
Transcat Inc (TRNS) filed this Current Report (Form 8-K) with the SEC on March 9, 2026. The accession number assigned by EDGAR is 0001206774-26-000129.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Transcat names Jaime Irick as CEO effective March 29, 2026; Rudow resigns from the Board to a senior advisory role. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Transcat Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Transcat Inc has filed under CIK 99302, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer